ACXP - יחס חוב להיוון בספרים acurxpharma.com

Unique patents for targeted antibiotics that block generics serve as the foundation for Acurx Pharmaceuticals (ACXP) growth. The company's debt-to-equity ratio, as calculated by GURU.Markets quotes, confirms this, with the current level sitting around 0.00. External conditions include partnerships with microbiome laboratories and commercialization risks following Phase II trials, which necessitate external financing.

Antibiotic development and the implementation of ESG waste disposal standards at Acurx Pharmaceuticals (ACXP) correlate directly with the current ratio of debt to balance sheet equity. This indicator measures the proportion of borrowed funds relative to the company's own equity. The ratio of total liabilities to the book value of assets determines the level of financial leverage. A decrease in this coefficient minimizes bankruptcy risk. A stable trend confirms the business's ability to fund environmental innovations without a critical debt burden.